Evidence map›Paper›PMID 41667461›Full record

ArticleNature communications2026

Ecological partitioning enables phage-antibiotic cooperation in a human Pseudomonas infection.

Tiffany Luong, Lukeman Kharrat, Kevin Champagne-Jorgensen, Jennifer A Melendez, David Pride, Douglas J Conrad, Dwayne R Roach

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tiffany LuongDepartment of Biology, San Diego State University, San Diego, CA, USA.ORCID 0000-0002-7694-277X
Lukeman KharratDepartment of Biology, San Diego State University, San Diego, CA, USA.ORCID 0009-0009-7193-1543
Kevin Champagne-JorgensenDepartment of Biology, San Diego State University, San Diego, CA, USA.ORCID 0000-0002-1445-1449
Jennifer A MelendezDepartment of Biology, San Diego State University, San Diego, CA, USA.
David PrideDepartment of Pathology, University of California San Diego, San Diego, CA, USA.
Douglas J ConradDivision of Pulmonary, Critical Care, and Sleep Medicine, San Diego, CA, USA.
Dwayne R RoachDepartment of Biology, San Diego State University, San Diego, CA, USA. dwayne.roach@sdsu.edu.ORCID 0000-0002-2069-8915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacteriophage-antibiotic coadministration is increasingly used for refractory infections, yet the in vivo interactions among phages, bacteria, antibiotics, and host immunity remain poorly defined. We report a longitudinal, multiomic case analysis of a male in his seventies with cystic fibrosis (CF) experiencing an acute-on-chronic pulmonary exacerbation caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. After colistin discontinuation due to nephrotoxicity, ciprofloxacin was initiated, with an intravenous two-phage cocktail introduced days later. Distinct mucoid and nonmucoid bacterial subpopulations associated differentially with antibiotic versus phage exposure, consistent with nonoverlapping selective pressures. Phage activity was temporally constrained, with one phage dominating early bacterial and genomic signals before attenuating after approximately seven days, despite continued genomic detectability. In contrast, the second phage showed no evidence of productive activity. This asymmetry coincided with phage-reactive humoral immunity: pre-existing IgM was associated with lack of recoverability of one phage, while treatment-associated IgM emergence temporally tracked attenuation of the dominant phage. Although phage-resistant variants arose during therapy, they showed limited expansion relative to susceptible populations. These findings define a mechanistic framework-chemobiotherapy-in which chemical and biological antimicrobials coordinate through ecological and immunologic complementarity rather than direct pharmacologic synergy.

Indexed as

Anti-Bacterial AgentsBacteriophagesPseudomonas aeruginosaPseudomonas InfectionsPseudomonas PhagesCiprofloxacinCystic FibrosisDrug Resistance, Multiple, BacterialHumansMalePhage TherapyAnti-Bacterial AgentsCiprofloxacin

Identifiers

PMID41667461
PMCPMC13003088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.